C

CytoTools AG
XETRA:T5O

Watchlist Manager
CytoTools AG
XETRA:T5O
Watchlist
Price: 101.26 EUR 0.98%
Market Cap: 52.8m EUR
Have any thoughts about
CytoTools AG?
Write Note

P/E
Price to Earnings

-79.9
Current
-63.6
Median
23.3
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-79.9
=
Market Cap
52.8m EUR
/
Net Income
-660.7k EUR
All Countries
Close
Earnings Growth
DE
C
CytoTools AG
XETRA:T5O
Average P/E: 56.7
Negative Multiple: -79.9
N/A
US
Abbvie Inc
NYSE:ABBV
63
406%
US
Amgen Inc
NASDAQ:AMGN
55.3
74%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -255
38%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.7
56%
US
Gilead Sciences Inc
NASDAQ:GILD
102.9
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.7 N/A
AU
CSL Ltd
ASX:CSL
36.8
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.8 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -522.4 N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -56.8 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-12.9
2-Years Forward
P/E
-12.9
3-Years Forward
P/E
-13.8

See Also

Discover More